EuroBiotech: More Articles of Note

> The Committee for Medicinal Products for Human Use (CHMP) recommended approving Santhera Pharmaceuticals' (SIX:SANN) Raxone drug for the treatment of Leber's hereditary optic neuropathy. Santhera is now waiting on the adoption of the decision by the European Commission, after which it will have a 10-year window of exclusivity in which to market the orphan drug. Release

Zealand's (CPH:ZEAL) glucagon analogue ZP4207 came through a Phase I trial unscathed. The data suggest ZP4207 is safe and well tolerated in Type 1 diabetics, an outcome Jefferies analyst Peter Welford views as the first step in a rapid advance toward Phase II/III trial. Welford has pencilled in a possible regulatory filing for as soon as the first half of 2018. Release

Ipsen (EPA:IPN) presented an outline of its vision for the business by 2020, in which it set its sights on growing its sales to €2 billion ($2.2 billion). The target is for organic sales of drugs including current pipeline molecules. Ipsen plans to supplement these existing assets by snapping up programs in therapeutic areas adjacent to its core business. Assets against gastrointestinal and orphan cancers are top of its wish list. Release

Merck Serono committed €10 million ($11 million) to its biotech incubator in Israel. The money will allow Merck Serono to bring more startups into the incubator, which currently houses three firms. "We will definitely extend our activity. We have room for seven or eight companies in the incubator," CEO Karl-Ludwig Kley said at an event attended by Reuters. Reuters

Ablynx (EBR:ABLX) outlicensed the rights to its anti-TNFa rheumatoid arthritis drug ozoralizumab in Japan to Taisho Pharmaceutical. The deal nets Ablynx a $3 million (€2.7 million) upfront fee and positions it to ring the till as milestones and royalties trickle in. The deal is the second of its kind Ablynx has struck for ozoralizumab in Asia. The first was inked in September when Eddingpharm picked up the rights to the asset in China. Release

> The U.S. government exercised several options to have Bavarian Nordic (CPH:BAVA) develop a vaccine against Marburgvirus, part of the Filovirus family. The deal will add $15 million (€14 million) to Bavarian Nordic's bank account over the next few years, swelling the total size of the deal to $33 million. In return for the cash, Bavarian Nordic will advance its vaccine into Phase I, a process that will begin with the running of additional preclinical tests. Release

Transgene outlined plans to shed 120 jobs. The cuts are part of a rethink triggered by the loss of its alliance with Novartis ($NVS). Once the changes are completed, Transgene will have dropped its dream of vertical integration in favor of being a R&D-focused, service provider-reliant biotech. The French biotech is working with top shareholder Institut Mérieux to find roles for the affected staff. FierceBiotech